CoChat
Sign Up
Cited by 10

The DOI matches its Crossref record.

p85β regulatory subunit of class IA PI3 kinase negatively regulates mast cell growth, maturation, and leukemogenesis

Krishnan, Subha, Mali, Raghuveer Singh, Ramdas, Baskar, Sims, Emily, Ma, Peilin, Ghosh, Joydeep, Munugalavadla, Veerendra, Hanneman, Philip, Beane, Joal D., Kapur, Reuben·2012·Blood
DOI 10.1182/blood-2011-05-355602
Open this paper in CoChat — free account

Abstract

We show that loss of p85α inhibits the growth and maturation of mast cells, whereas loss of p85β enhances this process. Whereas restoring the expression of p85α in P85α−/− cells restores these functions, overexpression of p85β has the opposite effect. Consistently, overexpression of p85β in WT mast cells represses KIT-induced proliferation and IL-3–mediated maturation by inhibiting the expression of Microphthalmia transcription factor. Because p85α and p85β differ in their N-terminal sequences, chimeric proteins consisting of amino or carboxy-terminal of p85α and/or p85β do not rescue the growth defects of p85α−/− cells, suggesting cooperation between these domains for normal mast cell function. Loss of p85β impaired ligand induced KIT receptor internalization and its overexpression enhanced this process, partly because of increased binding of c-Cbl to p85β relative to p85α. In vivo, loss of p85β resulted in increased mast cells, and bone marrow transplantation of cells overexpressing p85β resulted in significant reduction in some tissue mast cells. Overexpression of p85β suppressed the growth of oncogenic KIT-expressing cells in vitro and prolonged the survival of leukemic mice in vivo. Thus, p85α and p85β differentially regulate SCF and oncogenic KIT-induced signals in myeloid lineage-derived mast cells.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2011-05-355602

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 47

  1. Kitamura, 1977, Development of mast cells from grafted bone marrow cells in irradiated mice., Nature, 268, 442, 10.1038/268442a0 · DOI
  2. Rodewald, 1996, Identification of a committed precursor for the mast cell lineage., Science, 271, 818, 10.1126/science.271.5250.818 · DOI · Paper page
  3. Galli, 2008, Immunomodulatory mast cells: negative, as well as positive, regulators of immunity., Nat Rev Immunol, 8, 478, 10.1038/nri2327 · DOI
  4. Maurer, 1998, The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells., J Exp Med, 188, 2343, 10.1084/jem.188.12.2343 · DOI
  5. Jensen, 2008, Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders., Br J Pharmacol, 154, 1572, 10.1038/bjp.2008.204 · DOI
  6. Tsai, 1991, The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo: analysis by anatomical distribution, histochemistry, and protease phenotype., J Exp Med, 174, 125, 10.1084/jem.174.1.125 · DOI
  7. Tsai, 1991, Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor., Proc Natl Acad Sci U S A, 88, 6382, 10.1073/pnas.88.14.6382 · DOI
  8. Nocka, 1990, Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors., EMBO J, 9, 3287, 10.1002/j.1460-2075.1990.tb07528.x · DOI
  9. Lemura, 1994, The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis., Am J Pathol, 144, 321
  10. Serve, 1995, Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells., EMBO J, 14, 473, 10.1002/j.1460-2075.1995.tb07023.x · DOI
  11. Ihle, 1983, Biologic properties of homogeneous interleukin 3: I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity., J Immunol, 131, 282, 10.4049/jimmunol.131.1.282 · DOI
  12. Ihle, 1992, Interleukin-3 and hematopoiesis., Chem Immunol, 51, 65
  13. Chabot, 1988, The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus., Nature, 335, 88, 10.1038/335088a0 · DOI · Paper page
  14. Kitamura, 1978, Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation., Blood, 52, 447, 10.1182/blood.V52.2.447.bloodjournal522447 · DOI · Paper page
  15. Tian, 1999, Activating c-kit gene mutations in human germ cell tumors., Am J Pathol, 154, 1643, 10.1016/S0002-9440(10)65419-3 · DOI
  16. Hirota, 1998, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors., Science, 279, 577, 10.1126/science.279.5350.577 · DOI
  17. Choe, 2006, c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK/T cell lymphomas., Leuk Lymphoma, 47, 267, 10.1080/10428190500281680 · DOI
  18. Jiao, 2009, AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2., Leukemia, 23, 1598, 10.1038/leu.2009.104 · DOI
  19. Metcalf, 2008, Hematopoietic cytokines., Blood, 111, 485, 10.1182/blood-2007-03-079681 · DOI
  20. Lantz, 1998, Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites., Nature, 392, 90, 10.1038/32190 · DOI · Paper page
  21. Fukao, 2002, Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice., Nat Immunol, 3, 295, 10.1038/ni768 · DOI
  22. Fruman, 1998, Phosphoinositide kinases., Annu Rev Biochem, 67, 481, 10.1146/annurev.biochem.67.1.481 · DOI
  23. Backer, 1992, Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation., EMBO J, 11, 3469, 10.1002/j.1460-2075.1992.tb05426.x · DOI
  24. Otsu, 1991, Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase., Cell, 65, 91, 10.1016/0092-8674(91)90411-Q · DOI
  25. Escobedo, 1991, cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor., Cell, 65, 75, 10.1016/0092-8674(91)90409-R · DOI
  26. Fruman, 1996, Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene., Genomics, 37, 113, 10.1006/geno.1996.0527 · DOI
  27. Pons, 1995, The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase., Mol Cell Biol, 15, 4453, 10.1128/MCB.15.8.4453 · DOI
  28. Terauchi, 1999, Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase., Nat Genet, 21, 230, 10.1038/6023 · DOI · Paper page
  29. Ueki, 2002, Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase., Proc Natl Acad Sci U S A, 99, 419, 10.1073/pnas.012581799 · DOI
  30. Mali, 2011, Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL., Cancer Cell, 20, 357, 10.1016/j.ccr.2011.07.016 · DOI
  31. Nishizumi, 1997, Impaired tyrosine phosphorylation and Ca2+ mobilization, but not degranulation, in lyn-deficient bone marrow-derived mast cells., J Immunol, 158, 2350, 10.4049/jimmunol.158.5.2350 · DOI
  32. Blume-Jensen, 1991, Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis., EMBO J, 10, 4121, 10.1002/j.1460-2075.1991.tb04989.x · DOI
  33. Broudy, 1999, Signaling via Src family kinases is required for normal internalization of the receptor c-Kit., Blood, 94, 1979
  34. Wisniewski, 1996, c-kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells., Leukemia, 10, 1436
  35. Zeng, 2005, Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl)., Blood, 105, 226, 10.1182/blood-2004-05-1768 · DOI
  36. Munugalavadla, 2007, Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis., Blood, 110, 1612, 10.1182/blood-2006-10-053058 · DOI
  37. Fruman, 2000, Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha., Nat Genet, 26, 379, 10.1038/81715 · DOI
  38. Chen, 2004, p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity., Mol Cell Biol, 24, 320, 10.1128/MCB.24.1.320-329.2004 · DOI
  39. Okkenhaug, 2001, New responsibilities for the PI3K regulatory subunit p85 alpha., Sci STKE, 2001, pe1, 10.1126/stke.2001.65.pe1 · DOI
  40. Deane, 2004, Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase., J Immunol, 172, 6615, 10.4049/jimmunol.172.11.6615 · DOI
  41. Miyazawa, 1994, Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells., Blood, 83, 137, 10.1182/blood.V83.1.137.137 · DOI
  42. Sargin, 2007, Flt3-dependent transformation by inactivating c-Cbl mutations in AML., Blood, 110, 1004, 10.1182/blood-2007-01-066076 · DOI
  43. Bandi, 2009, E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease., Blood, 114, 4197, 10.1182/blood-2008-12-190934 · DOI
  44. Masson, 2006, Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation., Biochem J, 399, 59, 10.1042/BJ20060464 · DOI
  45. Sulahian, 2009, Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia., Blood, 113, 5287, 10.1182/blood-2008-09-179572 · DOI
  46. Morii, 2004, Roles of MITF for development of mast cells in mice: effects on both precursors and tissue environments., Blood, 104, 1656, 10.1182/blood-2004-01-0247 · DOI
  47. Morii, 2001, Importance of leucine zipper domain of mi transcription factor (MITF) for differentiation of mast cells demonstrated using mi(ce)/mi(ce) mutant mice of which MITF lacks the zipper domain., Blood, 97, 2038, 10.1182/blood.V97.7.2038 · DOI

Cited by

Metadata

Authors
Krishnan, S., Mali, R. S., Ramdas, B., Sims, E., Ma, P., Ghosh, J., Munugalavadla, V., Hanneman, P., Beane, J. D., & Kapur, R.
Venue
Blood
Publisher
American Society of Hematology
Published
2012-04-26
Volume
119
Issue
17
Pages
3951-3961
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2011-05-355602
Cited by
10
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review